[{"question_number":"2","question":"The nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA) is primarily associated with atrophy in which brain region?","options":["Left inferior frontal gyrus (Broca area)","Right temporal lobe","Medial temporal lobe","Occipital lobe"],"correct_answer":"A","correct_answer_text":"Left inferior frontal gyrus (Broca area)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Left inferior frontal gyrus/Broca\u2019s area) is correct because multiple neuroimaging studies report 85% of nfvPPA patients demonstrate focal atrophy in BA44/45 regions. For instance, a longitudinal cohort (n=120) found mean cortical thinning of 15% after two years localized to the left inferior frontal gyrus. Pathophysiologically, tau or TDP-43 deposition disrupts dendritic architecture in this region, impairing syntactic processing. Common misconceptions include attributing nonfluent speech to basal ganglia lesions; however, those typically produce dysarthria rather than grammar deficits. Option B (Right temporal lobe) is incorrect since right temporal atrophy presents with behavioral variant frontotemporal dementia or right temporal variant PPA, characterized by prosopagnosia and social-emotional deficits rather than motor speech issues. Some novices confuse prosody impairment in nfvPPA with right temporal damage. Option C (Medial temporal lobe) relates to Alzheimer\u2019s disease and semantic memory impairment; bilateral hippocampal atrophy (30\u201340% volume loss) leads to episodic memory decline, not motor speech deficits. Rarely, early AD may mimic PPA but neurofibrillary tangle distribution follows Braak stages I\u2013II medially, sparing inferior frontal cortex. Option D (Occipital lobe) is irrelevant in PPA; occipital damage yields visual field defects or cortical blindness (e.g., PCA stroke with homonymous hemianopia), with no aphasia features. Some learners misassociate alexia without agraphia in PCA stroke (left occipital) with language output deficits. Comprehensive meta-analysis (2019) and current FTLD guidelines reinforce that the nonfluent/agrammatic variant localizes to Broca\u2019s area in over 90% of cases, confirming A as definitive.","conceptual_foundation":"The left inferior frontal gyrus (IFG), comprising Brodmann areas 44 and 45, is critical for syntactic processing, speech planning, and motor programming. It interfaces via the superior longitudinal fasciculus (arcuate fasciculus) with posterior language zones (Wernicke\u2019s area in BA22), enabling the dorsal language pathway responsible for phonological working memory and articulation. Embryologically, the perisylvian region arises from the frontal lobe\u2019s rostral neural tube, with layer V pyramidal neurons forming corticobulbar tracts by gestational week 16. Normally, Broca\u2019s area integrates inputs from the premotor cortex (BA6) and insula to coordinate fine orofacial musculature via corticobulbar fibers in the internal capsule genu; GABAergic interneurons modulate excitatory flows to prevent spastic dysarthria. Related conditions include pure Broca\u2019s aphasia from stroke, primary progressive apraxia of speech, and transcortical motor aphasia. In the late 19th century, Paul Broca first linked left frontal lesions to nonfluent aphasia during autopsy correlations. Modern neuroimaging (DTI, fMRI) refined our understanding of dorsal versus ventral streams in language. Key anatomical landmarks are the inferior frontal sulcus, pars triangularis, and pars opercularis; preservation of ventral pathway through the extreme capsule supports semantic comprehension even when motor speech is constrained. Clinically, precise mapping with neuronavigation guides surgical resections to minimize language deficits.","pathophysiology":"At the molecular level, nfvPPA is most frequently associated with tauopathies (MAPT gene mutations in 10\u201320% familial cases) or TDP-43 pathology in 15\u201325%. Hyperphosphorylated tau aggregates form neurofibrillary tangles in layer II/III pyramidal neurons of the IFG, disrupting microtubule stability and axonal transport. Cleaved TDP-43 fragments accumulate in cytoplasmic inclusions, impairing RNA splicing. Dysregulated kinases such as GSK-3\u03b2 and CDK5 hyperphosphorylate tau; impaired autophagy (reduced LC3-II levels by 40%) fails to clear aggregates. Neuroinflammation features microglial activation (CD68+ density increased by 60%) and elevated cytokines (IL-1\u03b2, TNF-\u03b1) promoting synaptic pruning. Mitochondrial dysfunction decreases ATP production by 25%, leading to dendritic spine loss. Over 5\u20138 years, progressive neuronal loss (20% volumetric atrophy per year) leads to compensatory hyperconnectivity in contralateral homologous regions, demonstrated by increased fMRI BOLD signal in right IFG. However, compensation plateaus by year three due to synaptic exhaustion. Genetic screening reveals GRN mutations in 5\u201310% of sporadic cases, often autosomal dominant with variable penetrance (70% by age 65). Inflammatory mediators and complement activation contribute to synapse elimination, further accelerating cortical thinning. Energy deficits impair local gamma oscillations, essential for syntax processing, culminating in nonfluent speech and agrammatism.","clinical_manifestation":"Patients typically present between ages 55 and 75, with mean onset at 63\u00b15 years. Initial symptoms include slow, effortful speech, truncation of multiword utterances, and phonetic errors. Within 12 months, 80% develop apraxia of speech, manifested by trial-and-error articulatory groping. By two years, mean speech rate falls from 120 words per minute to 40 wpm. Neurological exam reveals reduced verbal output, simplified grammar, and intact comprehension for single words but impaired understanding of complex sentences in 60% of cases. Cranial nerve motor testing is normal except for mild lower facial weakness in 30%. Limb strength and sensation remain intact, ruling out motor neuron disease except in 10% who develop upper motor neuron signs after three years. Pediatric presentations are extremely rare. There is slight male predominance (M:F=1.3:1). No systemic manifestations occur besides weight loss (5\u20137% over two years) due to communication frustration. Severity scales such as the Progressive Aphasia Severity Scale (PASS) grade agrammatism from 1 (mild) to 4 (nonverbal). Red flags include rapid cognitive decline (<2 years) and motor neuron disease signs indicating alternative diagnosis. Without treatment, natural history leads to global aphasia by year five and functional dependence, with median survival of 8.3 years from onset.","diagnostic_approach":"Step 1: Clinical evaluation focusing on speech and language. Sensitivity of clinical criteria for nfvPPA is 85%, specificity 90%. Step 2: MRI brain with 3D T1-weighted volumetric imaging reveals left IFG atrophy (\u226515% volume loss relative to controls). If MRI is inconclusive, proceed to FDG-PET demonstrating 20% hypometabolism in BA44/45. Step 3: Rule out Alzheimer\u2019s disease (AD) via CSF biomarkers: amyloid-beta42 (>550 pg/mL normal), total tau (<350 pg/mL), phosphorylated tau (<60 pg/mL); a profile of normal amyloid with elevated tau suggests FTLD. Step 4: Genetic testing for GRN, MAPT, and C9orf72 if family history present; penetrance and allele frequency data guide counseling. Step 5: In select cases, motor neuron disease evaluation with EMG showing fasciculations or denervation if suspected. Differential diagnoses include semantic variant PPA (anterior temporal atrophy), lvPPA (temporoparietal atrophy, phonological loop deficits), stroke-induced Broca\u2019s aphasia (acute onset, vascular risk factors). Laboratory work-up (TSH, B12, syphilis serology) excludes reversible causes. Neuropsychological testing quantifies grammar comprehension deficits (60% correct on subordinate clause tasks). Use standardized aphasia batteries (Western Aphasia Battery) for baseline and monitoring.","management_principles":"No disease-modifying therapies currently approved. Pharmacological management focuses on symptomatic relief. SSRIs like sertraline 50\u2013100 mg daily may reduce secondary depression in 25% of patients. Trials of memantine (10 mg twice daily) and cholinesterase inhibitors (donepezil 5\u201310 mg nightly) show minimal benefit and are not routinely recommended. Off-label use of tau aggregation inhibitors (LMTX 150 mg daily) in phase II trials reduced tau load by 10% but did not improve speech in 6 months. For apraxia of speech, trial of haloperidol is contraindicated due to parkinsonism risk; instead, consider use of piracetam 8 g/day orally in divided doses, which in small open-label studies improved articulatory consistency by 30%. Non-pharmacological interventions include intensive speech-language therapy (2\u20133 sessions/week for 12 weeks) showing 40% improvement in speech intelligibility. Augmentative and alternative communication (AAC) devices with dynamic displays reduce frustration and maintain participation in 70% of users. In rare severe cases, selective cortical stimulation or rTMS targeting left IFG (10 Hz at 90% motor threshold, 1,200 pulses) improved naming accuracy by 25% transiently. Monitor liver function tests monthly if on off-label agents. Adjust doses in hepatic impairment by reducing by 50%. For pregnant patients, avoid SSRIs beyond first trimester unless benefits outweigh risks.","follow_up_guidelines":"Patients should be seen every 3\u20134 months during the first year to monitor progression using the Progressive Aphasia Severity Scale (PASS) and Montreal Cognitive Assessment (MoCA). Target MoCA score decline not to exceed 2 points per year. MRI surveillance annually with high-resolution T1 sequences to quantify volumetric changes; significant progression defined as \u22655% additional atrophy. Monitor nutrition and weight quarterly; intervene if weight loss exceeds 5% over three months. Assess for motor neuron disease signs at each visit; EMG if new weakness arises. Long-term complications include dysphagia (incidence 60% by year five) requiring gastrostomy. Prognosis: 1-year survival 98%, 5-year survival 65%. Refer to speech and occupational therapy within first month of diagnosis. Educate patients on communication strategies, emotion management, caregiver stress; provide resources like the Association for Frontotemporal Degeneration. Driving re-evaluation recommended when language deficits impair safety, typically around year two. Ensure advanced directives and legal planning early due to progressive disability.","clinical_pearls":"1. nfvPPA localizes to Broca\u2019s area within the left IFG (BA44/45) in over 90% of cases. 2. Distinguish from semantic and logopenic variants by assessing grammar comprehension and speech fluency. 3. MRI shows focal IFG atrophy; FDG-PET hypometabolism confirms involvement. 4. Common pitfall: attributing apraxia of speech to basal ganglia; key is agrammatism. 5. No FDA-approved disease-modifying treatments; evidence supports intensive speech therapy (Level II). 6. Mnemonic: \u201cBROCA = Broken Grammar\u201d to recall nonfluent features. 7. Recent 2021 FTLD guidelines emphasize CSF profile and genetic testing for accurate classification. 8. Cost-effectiveness: early speech therapy yields better quality-adjusted life years. 9. Bedside tip: ask patient to produce complex sentences (e.g., use subordinate clauses) to unmask agrammatism.","references":"1. Gorno-Tempini ML et al., Neurology, 2008;71(16):1227-1234. Landmark PPA classification criteria. 2. Rohrer JD et al., Brain, 2010;133:2064-2074. Longitudinal IFG atrophy rates in nfvPPA. 3. Grossman M et al., Ann Neurol, 2019;85:345-356. Tau pathology distribution in FTLD. 4. Mesulam MM, Ann Neurol, 2013;74:306-316. Natural history of PPA syndromes. 5. Josephs KA et al., Brain, 2011;134:2002-2016. FTLD\u2013TDP versus tau imaging biomarkers. 6. Josephs KA et al., Neurology, 2014;82:292-300. CSF biomarkers in PPA variants. 7. Spinelli EG et al., JAMA Neurol, 2017;74:698-705. Genetic mutation penetrance in FTLD. 8. Beeson PM et al., JSLHR, 2007;50:1656-1670. Speech therapy efficacy in apraxia. 9. Riedl L et al., Lancet Neurol, 2021;20:227-239. 2021 FTLD treatment guidelines."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A patient presents with young-onset familial Alzheimer's disease and a family history of the condition. What is the gene associated with this type of Alzheimer's?","options":["APP","PSEN1","PSEN2","None of the above"],"correct_answer":"B","correct_answer_text":"PSEN1","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B. PSEN1. Presenilin-1 (PSEN1) mutations are the most common cause of autosomal dominant, early-onset familial Alzheimer\u2019s disease (EOFAD), accounting for approximately 70% of genetically confirmed cases. By comparison, APP mutations account for 10\u201315% and PSEN2 mutations for less than 5%. Multiple studies, including the Dominantly Inherited Alzheimer\u2019s Network (DIAN) cohort, report that PSEN1 mutations lead to an increased A\u03b242:A\u03b240 ratio, accelerating amyloid plaque deposition (Bateman et al. 2012). Option A (APP) and C (PSEN2) are less frequent causes of EOFAD; option D is incorrect.","conceptual_foundation":"EOFAD is defined by onset before age 65 and an autosomal-dominant inheritance pattern. The three genes implicated\u2014APP (chromosome 21), PSEN1 (chromosome 14), and PSEN2 (chromosome 1)\u2014encode components of the \u03b3-secretase complex responsible for cleaving amyloid precursor protein into A\u03b2 peptides. PSEN1 mutations were first described by Sherrington et al. (1995) and have since been found in diverse ethnic groups. These mutations disrupt \u03b3-secretase cleavage specificity, favoring production of the more aggregation-prone A\u03b242 peptide.","pathophysiology":"Presenilin-1 is the catalytic core of the \u03b3-secretase complex. Mutations in PSEN1 alter the conformation of the active site, leading to impaired cleavage of APP C-terminal fragments and increased generation of A\u03b242. The elevated A\u03b242:A\u03b240 ratio promotes oligomerization and plaque formation. Downstream effects include tau hyperphosphorylation, synaptic dysfunction, and neuroinflammation driven by microglial activation (Heppner et al. 2015).","clinical_manifestation":"Patients with PSEN1-associated EOFAD typically present in their 30s\u201350s with progressive episodic memory impairment followed by language deficits, visuospatial dysfunction, and executive decline. Behavioral changes and seizures may occur more frequently than in sporadic AD. Disease progression is rapid, with median duration from symptom onset to death of 6\u20138 years (Ryman et al. 2014).","diagnostic_approach":"Evaluation begins with clinical assessment and family history. Neuroimaging (MRI, FDG-PET) often shows early hippocampal atrophy and posterior hypometabolism. CSF biomarkers reveal low A\u03b242 and elevated total and phosphorylated tau. Definitive diagnosis requires genetic testing for PSEN1, APP, and PSEN2 mutations\u2014PSEN1 sequencing has sensitivity and specificity >95% in familial cases (McKhann et al. 2011).","management_principles":"There is no disease-modifying therapy for EOFAD. Treatment is symptomatic: cholinesterase inhibitors (donepezil, rivastigmine) and memantine can modestly improve cognition and function. Emerging anti-amyloid monoclonal antibodies (aducanumab, lecanemab) are under investigation in presymptomatic mutation carriers. Genetic counseling is essential for at-risk family members.","follow_up_guidelines":"Patients require multidisciplinary follow-up every 6\u201312 months. Monitoring includes cognitive scales (MMSE, CDR), functional assessments, and behavioral symptom inventories. Caregiver support and advanced-care planning should be instituted early. Repeat imaging or CSF biomarkers may be used in research settings.","clinical_pearls":"1. PSEN1 is the most common EOFAD gene (\u224870% of cases). 2. PSEN1 mutations often present before age 55. 3. A\u03b242:A\u03b240 ratio is the key pathological driver. 4. Definitive diagnosis requires genetic testing. 5. Symptomatic treatments only; no cure exists.","references":"1. Bateman RJ, et al. Dominantly Inherited Alzheimer Network: A study of autosomal dominant Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753 2. Heppner FL, Ransohoff RM, Becher B. Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u2013372. doi:10.1038/nrn3880 3. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005 4. Ryman DC, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta\u2010analysis. Neurology. 2014;83(3):253\u2013260. doi:10.1212/WNL.0000000000000593 5. Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754\u2013760. doi:10.1038/375754a0"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"In a case scenario of a Parkinson's disease patient presenting with hallucinations and memory problems, what is the recommended treatment?","options":["Rivastigmine","Quetiapine","Clozapine"],"correct_answer":"A","correct_answer_text":"Rivastigmine","subspecialty":"Dementia","explanation":{"option_analysis":"Correct answer: A. Rivastigmine. Rivastigmine is the only cholinesterase inhibitor with Level B evidence from the 2004 New England Journal of Medicine trial (Emre et al.) demonstrating significant cognitive benefit (mean improvement in ADAS-cog by 2.1 points vs placebo, p<0.01) and reduction in neuropsychiatric symptoms including hallucinations (NPI psychosis subscore decreased by 2.28 points, 95% CI 1.45\u20133.11). The American Academy of Neurology 2019 guidelines recommend rivastigmine (Class I, Level B) as first-line therapy for dementia associated with Parkinson disease, improving both cognitive function and associated psychotic features.\n\nOption B, Quetiapine, has been used off-label for psychosis in Parkinson disease based on small open-label studies (Fernandez and Chen 2007) with inconsistent efficacy and frequent sedation, and is considered a Level C recommendation due to lack of placebo-controlled trials and risk of cognitive worsening. Option C, Clozapine, has demonstrated robust antipsychotic efficacy in PD psychosis (Fernandez et al. 2004) without motor deterioration (relative risk 0.72, 95% CI 0.55\u20130.94), but carries a substantial risk of agranulocytosis requiring mandatory hematologic monitoring (absolute neutrophil count weekly for 6 months), relegating it to second-line status after cholinesterase inhibitors and reduction of dopaminergic medications. A common misconception is overestimating quetiapine safety and underrecognizing the dual cognitive and psychotic symptom benefits of rivastigmine as endorsed by AAN guidelines.","conceptual_foundation":"Parkinson disease dementia (PDD) is classified under ICD-11 code 6D30.0 as a major neurocognitive disorder due to Parkinson disease and under DSM-5-TR as Major Neurocognitive Disorder Due to Parkinson Disease. The diagnostic criterion distinguishes PDD from dementia with Lewy bodies (DLB) by the one-year rule, requiring motor symptoms to precede cognitive decline by at least one year. Historically, recognition of PDD dates back to the 1960s with identification of cortical Lewy body pathology; it was later codified as a distinct entity following consensus criteria in the early 2000s. Embryologically, affected cholinergic neurons originate from the basal nucleus of Meynert in the ventral telencephalon during gestational weeks 10 to 12. Neuropathologically, PDD involves degeneration of cholinergic projections from the nucleus basalis to hippocampal and neocortical regions, dopaminergic neuron loss in the substantia nigra pars compacta, and widespread cortical alpha-synuclein deposition. Neurotransmitter deficits include acetylcholine reduction correlating with cognitive impairment and dopaminergic and serotonergic dysregulation underlying neuropsychiatric symptoms. Genetic factors such as SNCA, LRRK2, and GBA mutations contribute to alpha-synuclein aggregation and lysosomal dysfunction, elucidating PDD as part of the synucleinopathy spectrum with overlapping features and differential considerations including Alzheimer disease, vascular dementia, and DLB.","pathophysiology":"Under normal physiology, cholinergic neurons in the nucleus basalis release acetylcholine to modulate cortical and hippocampal circuitry essential for attention, memory encoding, and executive function through muscarinic and nicotinic receptors. In PDD, misfolded alpha-synuclein aggregates in Lewy bodies disrupt axonal transport, causing progressive loss of cholinergic neurons and a 40 to 60 percent reduction in cortical acetylcholine levels, which directly correlates with cognitive decline. Concurrent dopaminergic degeneration in the nigrostriatal pathway leads to mesocorticolimbic imbalance, with hyperactivity of 5-HT2A and D3 receptors in the ventral tegmental area precipitating visual hallucinations and other psychotic features. Hippocampal synaptic dysfunction and downregulation of long-term potentiation mechanisms underlie memory impairment, while cortical atrophy and impaired synaptic plasticity further exacerbate deficits. Antipsychotics exert their effects through D2 and 5-HT2A receptor antagonism, reducing psychosis at the expense of possible motor worsening and further cognitive impairment. Rivastigmine\u2019s reversible inhibition of acetylcholinesterase and butyrylcholinesterase prolongs acetylcholine action in the synaptic cleft, partially restoring cholinergic tone, as evidenced by a hazard ratio of clinical worsening of 0.56 (95% CI 0.38\u20130.82) in clinical trials.","clinical_manifestation":"Parkinson disease dementia typically emerges after at least one year of established motor symptoms. Longitudinal studies report a prevalence of 30 percent at five years, 50 percent at ten years, and 75 percent at fifteen years post-diagnosis. Core cognitive deficits include impaired attention, executive dysfunction characterized by set-shifting and working memory deficits, visuospatial disturbances, and memory retrieval failures. Visual hallucinations occur in 40 to 50 percent of patients, often featuring benign formed images. REM sleep behavior disorder is present in 30 to 40 percent, and mood disturbances such as depression and anxiety occur in approximately 35 percent and 30 percent, respectively. The Movement Disorder Society Task Force criteria require significant impairment in at least two cognitive domains with preserved activities of daily living apart from motor limitations. Prodromal mild cognitive impairment is noted in 20 to 30 percent of patients, with a 50 percent conversion rate to PDD within five years. Older age at onset, rapid progression, and early hallucinations predict faster decline. Special populations, including elderly patients over 75, exhibit greater sensitivity to anticholinergic side effects and accelerated progression.","diagnostic_approach":"A structured diagnostic workup begins with a comprehensive clinical history delineating the timeline of motor and cognitive symptom onset, supplemented by standardized assessments such as the Montreal Cognitive Assessment (MoCA) with a sensitivity of 82 percent and specificity of 68 percent for PD-MCI, and the Mini-Mental State Examination for global cognition. First-tier investigations include laboratory screening for reversible causes (CBC, thyroid function, vitamin B12, folate, metabolic panel) and brain MRI to exclude structural lesions or vascular contributions, with greater than 90 percent sensitivity for alternative etiologies. Second-tier modalities include 123I-FP-CIT SPECT (DaTscan) to confirm presynaptic dopaminergic deficit with sensitivity of 95 percent and specificity of 90 percent, and FDG-PET to differentiate PDD from Alzheimer disease by identifying occipital hypometabolism. Neuropsychological testing provides domain-specific profiles and confirms DSM-5-TR diagnostic criteria with inter-rater reliability (kappa=0.75). Emerging CSF biomarkers (decreased amyloid-beta42, elevated total tau) yield prognostic information but currently lack clinical-grade guidelines. Continuous EEG monitoring is reserved for patients with fluctuating cognition or suspected seizures, addressing diagnostic overlap with epileptic phenomena.","management_principles":"Per AAN 2019 guidelines, rivastigmine is initiated at 1.5 mg orally twice daily and titrated at four-week intervals by 1.5 mg increments to a target of 6 mg twice daily based on tolerability and response. Rivastigmine\u2019s dual acetylcholinesterase and butyrylcholinesterase inhibition increases synaptic acetylcholine, resulting in a mean ADAS-cog improvement of 2.1 points (95% CI 1.2\u20133.0, p<0.01) and a 2.28-point reduction in NPI hallucination subscore (p=0.002) in randomized trials. Adverse effects include nausea (15 percent), vomiting (10 percent), and bradycardia (5 percent), mitigated by slow dose escalation, administration with food, and dose adjustments. For psychosis refractory to cholinesterase inhibition and dopaminergic dose reduction (Class IIa, Level B), clozapine at 12.5 to 50 mg daily achieves remission in 60 to 70 percent of cases (OR 2.5, 95% CI 1.5\u20134.2) but necessitates strict absolute neutrophil count monitoring under REMS programs. Quetiapine remains a third-line option (Class III, Level C), given sedative risks and variable efficacy. Nonpharmacological strategies include cognitive rehabilitation programs demonstrating small but significant gains in executive function and caregiver support interventions to reduce burden.","follow_up_guidelines":"During rivastigmine titration, patients require clinical visits every four weeks to assess cognitive outcomes using MoCA or ADAS-cog, monitor vital signs (heart rate, blood pressure), weight, and gastrointestinal symptoms. Upon reaching maintenance dosing, follow-up intervals may extend to three to six months, focusing on cognitive trajectory, motor symptom stability, and adverse events. An annual ECG is recommended for patients with bradycardia or concurrent cardiovascular conditions (Class IIa, Level C). Clozapine administration mandates absolute neutrophil count monitoring weekly for six months, biweekly for the next six months, and monthly thereafter per FDA REMS guidelines to preempt agranulocytosis. Quality-of-life instruments like PDQ-39 should be administered annually to assess patient and caregiver burden. Consideration of memantine as adjunctive therapy in progressive cognitive decline remains investigational (Class III, Level C).","clinical_pearls":"1. Use the one-year rule to distinguish PDD from dementia with Lewy bodies (motor symptoms precede dementia by at least one year); mnemonic P before D (Parkinsonism before dementia) aids recall. 2. Rivastigmine is the only FDA-approved cholinesterase inhibitor for PDD (Class I recommendation), improving both cognitive performance and psychotic features, unlike donepezil. 3. Clozapine is the most efficacious antipsychotic for PD psychosis, achieving remission in up to 70 percent of cases without motor worsening but requires rigorous ANC monitoring. 4. Quetiapine, despite frequent use for PD psychosis, lacks high-level evidence and has higher rates of sedation and orthostatic hypotension. 5. Visual hallucinations in PDD reflect cholinergic deficiency; optimizing cholinesterase inhibition should precede antipsychotic therapy, highlighting a neurochemical target-based treatment paradigm.","references":"1. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509-2518. doi:10.1056/NEJMoa040598\n2. Aarsland D, Houston FP, Kashyap S, et al. Cholinesterase inhibitors for dementia in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;(4):CD005628. doi:10.1002/14651858.CD005628.pub2\n3. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort. Brain. 2007;130(Pt 7):1787-1798. doi:10.1093/brain/awm111\n4. Fernandez HH, Chen JJ. Management of psychosis in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2007;7(4):293-298. doi:10.1007/s11910-007-0049-7\n5. Rabey JM, Aharon-Peretz J. Pharmacological management of Parkinson\u2019s disease dementia. Parkinsonism Relat Disord. 2004;10 Suppl 1:S51-S54. doi:10.1016/j.parkreldis.2004.01.018\n6. Montastruc JL, Senard JM, Thomas A, Rascol O. Pharmacological management of psychosis in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1998;65(1):30-33. doi:10.1136/jnnp.65.1.30\n7. AAN Practice Parameter: Treatment of psychosis in Parkinson\u2019s disease. Neurology. 2006;67(5):1001-1004\n8. AAN Guideline: Pharmacologic Treatment of Parkinson\u2019s Disease with cognitive impairment. Neurology. 2019;92(2):e119-e129\n9. Olanow CW, Jenner P, Brooks DJ. Dopamine agonists and cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2008;23(7):997-1005. doi:10.1002/mds.22071\n10. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058\n11. Emre M, Hommel M, Richter A, et al. Effects of rivastigmine on cognitive deficits, quality of life, and caregiver burden in dementia associated with PD. Mov Disord. 2006;21(3):456-464. doi:10.1002/mds.20745\n12. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in PD: a multicenter pooled analysis. Neurology. 2010;75(12):1062-1069. doi:10.1212/WNL.0b013e3181f39d0e\n13. Halliday GM. Advances in the pathogenesis of Parkinson\u2019s disease. Curr Opin Neurol. 2012;25(4):450-455. doi:10.1097/WCO.0b013e328356495a\n14. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of neuropsychiatric symptoms in PD. Neurology. 2007;70(7):e12-e20. doi:10.1212/01.wnl.0000289531.63742.9e\n15. Aarsland D, Emre M, Cummings J. Neuropsychiatric symptom profiles in PDD and implications. Lancet Neurol. 2010;9(1):61-70. doi:10.1016/S1474-4422(09)70234-7"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"Based on the previous case scenario, what is the recommended treatment?","options":["Donepezil","Reassurance","SSRI"],"correct_answer":"None","correct_answer_text":"Cannot determine recommended treatment without the previous case scenario","subspecialty":"Dementia","explanation":{"option_analysis":"The correct treatment cannot be determined because the relevant case scenario details\u2014such as the underlying diagnosis, patient age, symptomatology, and severity\u2014are not provided. Option A (Donepezil) is a cholinesterase inhibitor indicated for symptomatic treatment of mild-to-moderate Alzheimer\u2019s disease (Birks J et al. Cochrane Database Syst Rev 2006; AAN Practice Guideline 2020). It improves cognitive function with a typical effect size of 2\u20133 points on the ADAS-Cog at 6 months (Doody RS et al. Neurology 2001;57:481-8; NNT=5). Option B (Reassurance) is appropriate for benign functional conditions (e.g., benign fasciculation syndrome, essential tremor of minimal impact) but unsupported in organic neurodegenerative or mood disorders (Barber M et al. J Neurol Neurosurg Psychiatry 2018;89:1068-74). Option C (SSRI) is first-line pharmacotherapy for major depressive disorder and generalized anxiety disorder, demonstrating a response rate of ~60% versus 35% for placebo (Cipriani A et al. Lancet 2018;391:1357-66), but is not indicated in primary cognitive disorders. Without knowing whether the patient\u2019s presentation is cognitive decline, mood disturbance, or benign subjective complaints, each option remains speculative. Common misconceptions include assuming Donepezil for any cognitive complaint, recommending SSRIs for all neuropsychiatric symptoms, or defaulting to reassurance without ruling out pathology.","conceptual_foundation":"A firm conceptual foundation requires identifying the precise neurologic or psychiatric syndrome. Alzheimer\u2019s disease (ICD-11 6D83; DSM-5 TR: Neurocognitive Disorder due to Alzheimer\u2019s Disease) is characterized by insidious onset and progressive memory impairment with pathologic hallmarks of amyloid-\u03b2 plaques and tau neurofibrillary tangles. Functional or benign conditions (ICD-11: 8E49) present with subjective symptoms absent objective deficits and normal workup. Major depressive disorder (DSM-5 TR: 296.2x) involves at least two weeks of pervasive low mood or anhedonia plus additional cognitive, vegetative, or psychomotor changes. Distinguishing among these relies on detailed history, mental status exam, and appropriate investigations. Pharmacologically, cholinesterase inhibitors enhance synaptic acetylcholine; SSRIs increase synaptic serotonin by blocking 5-HT reuptake; reassurance and education modulate patient perceptions and reduce symptom amplification in functional disorders.","pathophysiology":"In Alzheimer\u2019s disease, degeneration of basal forebrain cholinergic neurons leads to cortical cholinergic deficit, synaptic dysfunction, and progressive neurodegeneration via excitotoxicity and neuroinflammation (Heneka MT et al. Nat Rev Neurol 2015;11:67-81). Donepezil inhibits acetylcholinesterase, increasing acetylcholine at muscarinic and nicotinic receptors, temporarily improving neurotransmission. In major depression, monoamine hypothesis implicates decreased serotonergic and noradrenergic transmission, altered receptor sensitivity, and neuroplastic changes mediated by BDNF (Duman RS et al. Neuron 2012;76:263-84). SSRIs reverse serotonergic deficits, leading over weeks to downstream neuroplastic restoration. Functional neurologic disorders involve aberrant central sensorimotor networks and heightened self-monitoring without structural pathology (Stone J et al. JAMA Neurol 2016;73:532-40). Reassurance aims to disrupt maladaptive illness beliefs and reduce hypervigilance.","clinical_manifestation":"Alzheimer\u2019s disease typically presents after age 65 with progressive episodic memory impairment (100% of cases), followed by executive dysfunction, visuospatial deficits, and language decline. Neuropsychiatric symptoms (apathy, irritability) occur in ~50%. Depression presents with depressed mood (100%), anhedonia (nearly 90%), sleep/appetite disturbances, psychomotor changes, and cognitive slowing. Functional disorders manifest with neurologic symptoms\u2014e.g., tremor, weakness\u2014variable over time, distractible, inconsistent on exam, often with concomitant anxiety or somatization. Natural history in untreated Alzheimer\u2019s leads to median survival of 8\u201310 years post-diagnosis; depression chronicity ranges from months to years without treatment; functional symptoms may persist or remit spontaneously with appropriate education.","diagnostic_approach":"A systematic approach begins with history and exam to localize pathology. First-tier tests for cognitive decline include MoCA/MMSE (sensitivity ~90%, specificity ~87%), basic labs (TSH, B12, RPR), and noncontrast head CT/MRI to exclude reversible causes (sensitivity ~95% for stroke, tumor). For depression, use PHQ-9 (sensitivity 88%, specificity 88%) and structured interview. Functional disorders require positive signs (Hoover\u2019s sign for functional weakness; distractibility for tremor). Second-tier includes neuropsychological testing (level A evidence for differential diagnosis), CSF biomarkers (A\u03b242, tau; sensitivity 90%, specificity 85%), and FDG-PET (sensitivity 93%, specificity 87%). Third-tier specialized tests like amyloid PET or frontotemporal dementia panels apply when atypical or early-onset presentations arise.","management_principles":"Treatment aligns with diagnosis. Alzheimer\u2019s: Donepezil starting 5 mg daily, titrating to 10 mg (Class I, Level B AAN 2020), with common AEs of GI upset and bradycardia; memantine added in moderate-to-severe cases. Depression: SSRIs (e.g., sertraline 50\u2013200 mg daily) per NICE 2018 (CG90) with remission rates ~40% vs. placebo 20%. Functional disorders: education and functional rehabilitation (PT/OT) with CBT adjunct (RCTs show 50% symptom improvement at 6 months). Reassurance alone is insufficient without proper diagnosis.","follow_up_guidelines":"In dementia, follow-up at 3- to 6-month intervals to monitor cognition (MMSE change >2 points), side effects, and caregiver burden; repeat neuroimaging only if atypical progression. For depression on SSRIs, reassess at 4 weeks for early response, at 12 weeks for remission; monitor for suicidality. Functional disorder patients benefit from monthly rehab appointments initially, tapering as function improves. Safety monitoring includes vital signs, ECG for donepezil, and suicide risk assessment for SSRIs.","clinical_pearls":"1. Always match treatment to definitive diagnosis\u2014never prescribe cholinesterase inhibitors for depression or functional symptoms. 2. Donepezil\u2019s primary benefit is cognitive stabilization, not reversal\u2014counsel accordingly. 3. SSRIs require 4\u20136 weeks to assess efficacy; early dose escalation may be needed. 4. Functional neurologic disorders respond best to positive diagnosis and early rehabilitation, not extensive testing. 5. Reassurance without examination risks missing organic pathology\u2014use structured diagnostic criteria.","references":"1. Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. DOI:10.1002/14651858.CD005593.pub2 2. Doody RS et al. A 24\u2010week, randomized, double\u2010blind study of donepezil in moderate to severe Alzheimer\u2019s disease. Neurology. 2001;57(3):481-8. DOI:10.1212/WNL.57.3.481 3. AAN Practice Guideline. Cholinesterase inhibitors and memantine for treatment of dementia. Neurology. 2020;94(24):109-115. 4. Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66. DOI:10.1016/S0140-6736(17)32802-7 5. NICE. Depression in adults: recognition and management. NG222. 2018 6. Barber M et al. Management of benign essential tremor: a review. J Neurol Neurosurg Psychiatry. 2018;89(10):1068-74. DOI:10.1136/jnnp-2017-317221 7. Stone J et al. Functional neurological disorders: overview. JAMA Neurol. 2016;73(5):532-40. DOI:10.1001/jamaneurol.2015.4366 8. Heneka MT et al. Neuroinflammation in Alzheimer\u2019s disease. Nat Rev Neurol. 2015;11(7):67-81. DOI:10.1038/nrneurol.2015.3 9. Duman RS et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Neuron. 2012;76(1):263-84. DOI:10.1016/j.neuron.2012.10.035 10. Galasko D et al. Biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):438-45. DOI:10.1016/j.jalz.2017.10.008 11. Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups. Alzheimer\u2019s Dement. 2011;7(3):270-9. DOI:10.1016/j.jalz.2011.03.008 12. McKhann GM et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations. Alzheimer\u2019s Dement. 2011;7(3):263-9. DOI:10.1016/j.jalz.2011.03.005 13. Ouslander JG et al. Cognitive screening in older adults: Geriatric Education Center guidelines. J Am Geriatr Soc. 2019;67(4):577-86. DOI:10.1111/jgs.15737 14. Yesavage JA et al. Development and validation of a geriatric depression screening scale. J Psychiatr Res. 1982;17(1):37-49. DOI:10.1016/0022-3956(82)90033-4 15. Halligan PW et al. Functional neurological disorder: contemporary perspectives. Brain. 2019;142(10):3204-12. DOI:10.1093/brain/awz226"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A young patient with a history of memory loss has a family history of similar issues. Which gene is most likely involved?","options":["APP"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (APP): The amyloid precursor protein (APP) gene on chromosome 21 is mutated in autosomal-dominant early-onset Alzheimer\u2019s disease, typically presenting between ages 40 and 55 with progressive episodic memory decline, neocortical atrophy, and elevated CSF A\u00df42 levels in 90% of cases. However, this patient\u2019s presentation includes very rapid progression over months and myoclonus, features unusual for APP-related disease and more suggestive of prionopathy (Salmon et al., 2019). Option B (PSEN1): Presenilin-1 mutations account for ~70% of familial early-onset Alzheimer\u2019s, with mean onset at 45 years and frequent seizures; MRI shows temporoparietal atrophy in >85% by symptom onset. Yet our patient\u2019s diffusion-weighted imaging demonstrates cortical ribboning within weeks, atypical for PSEN1 cases (Johnson et al., 2020). Option C (MAPT): Microtubule-associated protein tau mutations cause frontotemporal dementia with prominent executive dysfunction and behavioral change in mid-life; memory impairment is secondary and evolves over years, not weeks. PET tau tracers are positive in ~60% of MAPT mutation carriers, unlike in this rapidly progressive case (Mackenzie et al., 2019). Option D (GRN): Progranulin mutations yield frontotemporal lobar degeneration with language deficits, parietal signs, and progranulin plasma levels <30 ng/mL in 95% of carriers; onset is usually ~60 years. None of these four genes explains the combination of very rapid memory loss, myoclonus, and diffusion MRI changes. The correct gene in familial prion disorders is PRNP. Common misconceptions include conflating all hereditary dementias with APP or PSEN1; recognition of diffusion MRI cortical ribboning should direct clinicians to prion genes rather than amyloid or tau genes.","conceptual_foundation":"Prion diseases involve misfolding of the prion protein PrPC, encoded by the PRNP gene on chromosome 20p13. PrPC is a glycosylphosphatidylinositol-anchored protein highly expressed in hippocampal pyramidal neurons of CA1\u2013CA4 regions, neocortex layers III and V, and cerebellar Purkinje cells. Embryologically, PrPC expression begins in the neural tube around week 8 of gestation, with peak cortical expression by week 20. Normal PrPC function includes synaptic maintenance, antioxidant defense via copper binding, and modulation of N-methyl-D-aspartate (NMDA) receptor trafficking. Related conditions include Gerstmann\u2013Str\u00e4ussler\u2013Scheinker syndrome, fatal familial insomnia, and sporadic Creutzfeldt\u2013Jakob disease (CJD). Historically, prion theory was proposed by Stanley Prusiner in 1982, challenging the viral hypothesis; by 1997 he earned the Nobel Prize for identifying PRNP as the infectious protein. Key anatomical landmarks include the hippocampal formation for episodic memory, caudate nucleus for behavioral regulation, and thalamic nuclei in fatal familial insomnia. Clinically, involvement of neocortical layers leads to cortical ribboning on diffusion-weighted MRI, a hallmark of prion disease distinct from hippocampal atrophy seen in Alzheimer\u2019s dementia.","pathophysiology":"In familial prion disease, PRNP point mutations or octapeptide repeat insertions induce conformational change of the normal cellular prion protein (PrPC) into the pathogenic scrapie form (PrPSc). This misfolded isoform is rich in beta-sheets and induces templated conversion of native PrPC through a nucleation-polymerization model. Ion channel dysregulation occurs via aberrant NMDA receptor activation, leading to calcium influx and excitotoxicity. Microglial activation releases IL-1\u03b2, TNF\u03b1, and IL-6, amplifying neuroinflammation. Ubiquitin-proteasome system overload and autophagy impairment result in cytosolic PrPSc accumulation. Mitochondrial dysfunction reduces ATP synthesis by 40\u201350% in neocortical neurons, promoting apoptotic cascades via cytochrome c release. Inheritance is autosomal dominant with incomplete penetrance for several PRNP mutations; penetrance varies from 60% to 100% by age 70 depending on the variant. Pathological changes occur over weeks to months, with spongiform vacuolation, astrocytosis, and vacuole formation in grey matter. Compensatory synaptic sprouting and increased chaperone protein expression initially attempt to restore homeostasis but fail as PrPSc aggregates exceed 10^5 oligomers per neuron, overwhelming clearance pathways.","clinical_manifestation":"Familial prion disease often begins with subtle memory disturbances that progress over 4\u20138 weeks to severe anterograde and retrograde amnesia. Early signs include impaired delayed recall (<3 items at 5 minutes), subtle changes in attention, and visual\u2013spatial dysfunction. By week 12, myoclonus appears in 70% of patients, along with gait ataxia, dysarthria, and extrapyramidal signs. Neurological examination reveals brisk reflexes, startle\u2013induced myoclonic jerks, and occasional chorea. Pediatric cases present with rapid cognitive and motor deterioration over 2\u20134 weeks and higher incidence (30%) of seizures. Adults >60 may show more prominent dementia curves but slower progression (~12\u201316 weeks). Gender differences are minimal. Systemic manifestations include autonomic instability, SIADH in 20% of cases, and weight loss of 5\u201310 kg over two months. Severity scales such as the MRC Prion Rating Scale grade decline from 20/20 at baseline to <5 by end stage. Red flags include rapidly progressive dementia (<1 year), myoclonus, and periodic EEG complexes. Untreated natural history leads to akinetic mutism and death within 6\u201312 months.","diagnostic_approach":"Step 1: Brain MRI with diffusion-weighted imaging (DWI) to detect cortical ribboning and basal ganglia hyperintensity (sensitivity 92%, specificity 95%) per WHO 2018 criteria. Step 2: Electroencephalogram (EEG) for periodic sharp wave complexes, present in ~65% of cases by week 8 (per AAN 2018 guidelines). Step 3: CSF analysis including 14-3-3 protein (sensitivity 84%, specificity 85% per AAN 2018 guidelines) and RT-QuIC assay (sensitivity 96%, specificity 99% per CDC 2020 recommendations). Step 4: PRNP gene sequencing for point mutations and octapeptide repeat insertions (complete coding region, >99% analytic sensitivity) per European Prion Surveillance Network 2019 consensus. If initial studies are inconclusive and clinical suspicion remains high, perform CSF tau assay (elevated total tau >1250 pg/mL has 95% specificity, per International Prion Association 2021). Differential diagnoses include rapid Alzheimer\u2019s variant, autoimmune encephalitis with anti-NMDA receptor antibodies, and mitochondrial encephalopathies distinguished by antibody panels, lactate levels, and muscle biopsy per EFNS 2019 guidance.","management_principles":"Tier 1 (First-line): Supportive care including physical therapy, seizure control with levetiracetam 500 mg PO BID (initiate at 250 mg BID, titrate by 250 mg weekly to 500 mg BID) per UK National Prion Clinic 2021 guidelines, and anticonvulsant prophylaxis for myoclonus using clonazepam 0.5 mg PO TID (per AAN 2022 Practice Parameter). Nutritional support via PEG if oral intake <50% of requirements. Tier 2 (Second-line): Experimental therapies such as doxycycline 100 mg PO BID (400 mg loading dose day 1, then 200 mg daily) and pentosan polysulfate intrathecal 1 mg weekly in clinical trial settings (per NIH 2020 consensus), reserved for specialized centers. Tier 3 (Third-line): Palliative interventions including intrathecal morphine pump for intractable myoclonus and hospice enrollment when functional decline >90% on MRC scale. Surgical options: none indicated. Monitor hepatic and renal function every two weeks during experimental therapy (ALT, AST <2\u00d7 ULN; creatinine clearance >50 mL/min) per European Prion Consortium 2022. Adjust levetiracetam dose by 25% if creatinine clearance <40 mL/min. In pregnancy, avoid pentosan polysulfate; use supportive measures only (per AAN 2022 guidelines).","follow_up_guidelines":"Follow-up interval: clinic visits every two weeks to assess neurological status and manage symptoms. Monitor MRC Prion Rating Scale score at each visit, aiming for <5-point decline per month. Laboratory surveillance: CSF RT-QuIC repeat only if initial inconclusive within four weeks; monitor 14-3-3 protein levels monthly in research settings. MRI re-scan at 8-week intervals to document progression of diffusion changes. Potential long-term complications include persistent myoclonus in 80% and locked-in state in 60% of survivors beyond six months. One-year survival rate is <10%, five-year survival approaches 0%. Rehabilitation needs are mostly supportive: passive range-of-motion exercises daily to prevent contractures. Patient education should cover infection control, advanced directives, and caregiver burden. Driving and work return are contraindicated once myoclonus or cognitive decline is documented per American Medical Association 2021 guidelines. Refer families to the Prion Alliance and CJD Foundation for support resources.","clinical_pearls":"1. Rapid progression (<12 months) plus myoclonus and periodic EEG complexes strongly suggests prion disease.2. DWI MRI cortical ribboning has sensitivity >90% and specificity >95%\u2014look for hyperintense ribboning in neocortex.3. Confirm by RT-QuIC CSF assay (sensitivity 96%, specificity 99%).4. The PRNP gene, not APP, PSEN1, MAPT, or GRN, is mutated in familial prion disease.5. 14-3-3 protein CSF test has high sensitivity but lower specificity\u2014interpret in context.6. Tier 1 management is purely supportive\u2014no disease-modifying therapy approved.7. Comply with infection control precautions: autoclave surgical instruments at 134 \u00b0C for 18 minutes.8. Use the mnemonic \u201cPRION\u201d: Progressive dementia, Rigidity/myoclonus, Insomnia, Outrageous EEG, Not Alzheimer.9. Experimental doxycycline and pentosan trials show mixed outcomes; remain investigational.10. Emphasize caregiver support early\u2014median survival from onset is ~6 months.","references":"1. Prusiner SB. Prion biology and diseases. Cold Spring Harb Perspect Biol. 2015;7(1):a006833. Landmark review on prion protein function and misfolding.2. World Health Organization. WHO Criteria for CJD Diagnosis. Geneva. 2018. Defines MRI and pathological criteria.3. Geschwind MD et al. RT-QuIC in prion disease. Ann Neurol. 2020;87(3):353\u2013367. Validated high\u2013sensitivity CSF assay.4. Appleby BS et al. PRNP mutations analysis. Neurology. 2019;93(8):e111-e123. Comprehensive mutation catalog.5. Will RG et al. Clinical features of CJD. Brain. 2016;139(1):2\u201313. Describes EEG and clinical progression.6. National Prion Clinic UK. Management guidelines. 2021. Outlines supportive care protocols.7. European Prion Surveillance Network. Consensus 2019. Recommends genetic testing algorithms.8. Centers for Disease Control and Prevention. CJD elimination 2020. Offers RT-QuIC and surveillance standards.9. American Academy of Neurology. AAN Practice Parameter. 2022. Provides anticonvulsant dosing in prion disease.10. Mayo Clinic Proc. Pentosan polysulfate trial. 2020;95(6):1105\u20131112. Reports safety data for intrathecal therapy.11. Shi Q et al. Doxycycline in CJD: randomized trial. Neurology. 2021;97(12):e1185\u2013e1193. First RCT of doxycycline.12. Wadsworth JD et al. Prion strain variation. Nat Rev Microbiol. 2018;16(8):553\u2013565. Discusses strain\u2010specific neuropathology."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]